Pharmaceuticals, Biotechnology and Life Sciences
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
Creso Pharma has appointed pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.
U.S. Food and Drug Administration (FDA) has approved Teva’s Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
Shield Therapeutics will welcome new Chief Financial Officer to the Group, who will be a Board member, in the beginning of the month of May 2017.
Following innovation platforms on epigenetics and microbiome, BASF has created a third research platform on extraction and processes that already produces results.
Kitov Pharmaceuticals Holdings Ltd, a NASDAQ and TASE listed innovative biopharmaceutical company, said Monday that that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application filing fee for Kitov’s patented combination of …
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
Novartis has been cleared in Europe for Tafinlar combined with Mekinist (dabrafenib with trametinib) to treat patients with BRAF V600-with advanced non-small cell lung cancer (NSCLC).